Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Monoethyl fumarate is used in the treatment of relapsing forms of Multiple Sclerosis (MS), supported by a substantial body of scientific evidence. Monoethyl fumarate is a bioequivalent active metabolite of dimethyl fumarate, which has been approved for MS based on large, randomized, placebo-controlled clinical trials (such as the DEFINE and CONFIRM studies). These studies demonstrated that fumarate esters significantly reduce relapse rates, decrease the number of new or enlarging lesions on MRI, and may slow disability progression in patients with relapsing-remitting MS.

The presumed mechanism of action involves activation of the Nrf2 (nuclear factor erythroid 2-related factor 2) antioxidant response pathway, which may protect against oxidative stress-induced neuronal damage, a contributor to MS pathology. Monoethyl fumarate is marketed as a separate entity (e.g., under the brand Bafiertam), and its efficacy and safety are considered comparable to those of dimethyl fumarate, as both are rapidly converted to the same active metabolite (monomethyl fumarate) in the body.

Common adverse effects include flushing and gastrointestinal symptoms, but the overall benefit-risk profile is favorable for many patients. While long-term safety data are still accumulating, the use of monoethyl fumarate for MS is justified by rigorous, peer-reviewed clinical research and regulatory approval, placing it among scientifically validated therapies for this condition.

More about Monoethyl fumarate
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Monoethyl fumarate

Products containing Monoethyl fumarate